Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)
Michael J. Kovacs(Western University), David Anderson(The Alfred Hospital), Shannon M. Bates(McMaster University), Elham Sabri(Ottawa Hospital), Susan Solymoss(Montreal General Hospital), Luljeta Pallaveshi(London Health Sciences Centre), Alejandro Lazo‐Langner(Western University), Susan R. Kahn(Jewish General Hospital), Marc Rodger(McGill University), Sam Schulman(Thrombosis and Atherosclerosis Research Institute), Philip S. Wells(Ottawa Hospital), Clive Kearon(McMaster University), Mark Blostein(Jewish General Hospital), Tim Ramsay(University of Ottawa)
Cited by 9
Related Papers
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
|Journal of Thrombosis and Haemostasis|2009|3.8k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
|New England Journal of Medicine|2009|2.6k